FAST-TRAC Award
The FAST-TRAC Award from FAST funds translational and preclinical research to develop new treatments and drug screening tools for Angelman syndrome, with a focus on gene and disease modification.
Funder: Foundation for Angelman Syndrome Therapeutics (FAST)
Due Dates: Rolling (applications accepted year-round)
Funding Amounts: Up to $150,000 per year for 1–2 years (higher amounts possible with justification)
Summary: Supports translational and preclinical research to advance new treatments for Angelman syndrome, with emphasis on gene/disease modification and drug screening tools.
Description
The FAST-TRAC Award, offered by the Foundation for Angelman Syndrome Therapeutics (FAST), is designed to accelerate translational and preclinical research that advances the development of new or improved treatments for Angelman syndrome. The award prioritizes projects focused on gene modification, disease modification, symptom-alleviating therapeutics, and the creation of innovative platforms or tools for high-throughput drug screening. Support is also available for the development of novel disease models, biomarkers, outcome measures, and preparation for clinical trials. The program aims to generate data that can lead to future grants, publications, and clinical progress for Angelman syndrome.
